Brentuximab Vedotin-Induced CIDP-Like Inflammatory Demyelinating Polyradiculoneuropathy (Clinical Case Report)

Brentuximab vedotin-induced inflammatory demyelinating polyradiculoneuropathy is a rare chemotherapy side effect. The underlying cause of disease is thought to be pathological drug effects on the humoral immune system. The typical clinical picture is characterized by progressive development of flaccid tetraparesis and severe polyneuritic manifestations, which typically leads to disability and significant impairment in quality of life. Nerve conduction study results show evidence of generalized primary demyelination, including conduction block and sural sparing pattern.Clinical and anamnestic data and objective observational findings are similar to the clinical and neurophysiological pattern observed in acute or recurrent inflammatory demyelinating polyradiculoneuropathies. It is important to emphasize that brentuximab vedotin-induced inflammatory demyelinating polyradiculoneuropathy response to accepted in guidelines pathogenic therapy, which includes corticosteroids, intravenous human immunoglobulin therapy and extracorporeal hemocorrection methods. Clinicians should be aware of treatment possibilities due to reversibility of neurological impairment through the pathogenetic immunosuppressive therapy. This clinical case represents a case of brentuximab-induced inflammatory demyelinating polyradiculoneuropathy with progressive development of severe motor impairment, which led to complete immobilization over 6 months. This clinical case report demonstrates optimal management strategy: timely administration of pathogenetic therapy with appropriate dosing, slow and gradual reduction in corticosteroid dosage. Competent management strategy ensures favorable outcome of the curable druginduced polyradiculoneuropathy.

1. Carlson K., Ocean A.J. Peripheral Neuropathy with MicrotubuleTargeting Agents: Occurrence and Management Approach. Clin Breast Cancer. 2011; 11 (2):73–81. DOI: 10.1016/j.clbc.2011.03.006.

2. Corbin Z.A., Nguyen-Lin A., Li S. et al. Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome. J Neurooncol. 2017; 132 (3):439–446. DOI: 10.1007/s11060-017-2389-9.

3. Gualberto A. Brentuximab Vedotin (SGN-35), an antibodydrug conjugate for the treatment of CD30-positive malignancies. Expert Opinion on Investigational Drugs. 2012; 21: 205–216. DOI: 10.1517/13-543784.2011.641532.

4. Kozlov A.V., Kazantzev I.V., Iukhta T.V. et al. Brentuximab vedotin in the treatment of children and adolescents with refractory and relapsed Hodgkin’s lymphoma. Pediatr Hematol Immunopathol. 2019; 18 (2):83–91. DOI: 10.24287/1726-1708-2019-18-2-83-91 [in Russian].

5. Matthys A., Bardel B., Le Bras F. et al. Rate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy. Eur J Neurol. 2024; 31 (7):e16285. DOI: 10.1111/ene.16285.

6. Pro B., Advani R., Brice P. et al. Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). J Clin Oncol. 2011; 29 (15_suppl):8032. DOI: 10.1200/jco.2011.29.15_suppl.8032.

7. Younes A., Gopal A.K., Smith S.E. et al. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin’s Lymphoma. J Clin Oncol. 2012; 30 (18):2183–2189. DOI: 10.1200/JCO.2011.38.0410.

8. Velasco R., Domingo-Domenech E., Sureda A. Brentuximab-induced peripheral neurotoxicity: A multidisciplinary approach to manage an emerging challenge in hodgkin lymphoma therapy. Cancers. 2021;13: 6125. DOI: 10.3390/cancers13236125.

9. Yi J.H., Kim S.J., Kim W.S. Brentuximab vedotin: clinical updates and practical guidance. Blood Res. 2017; 52 (4):243. DOI: 10.5045/br.2017.52.4.243.

10. Pezzullo L., Piscosquito G., Settembre L. et al. Electrophysiological Studies in Combination With Interim-Positron Emission Tomography Scan for Prevention of Severe Brentuximab-VedotinInduced Neurotoxicity. European Journal of Haematology. 2025; 114(5): 802-811. DOI: 10.1111/ejh.14384.

11. Mariotto S., Ferrari S., Monaco S. Brentuximab ve dotin-induced peripheral neuropathy: looking at microtubules. Journal of NeuroOncology. 2018; 137: 665–666. DOI: 10.1007/s11060-018-2743-6.

12. Pastorelli F., Derenzini E., Plasmati R. et al. Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leukemia and Lymphoma. 2013; 54: 2318–2321. DOI: 10.3109/10428194.2013.773997.

13. Hoffmann J.C., Soliman M., Koch J.C. et al. Demyelinating neuropathy and local toxicity caused by extravasated Brentuximab vedotin. Journal of the European Academy of Dermatology and Venereology. 2020; 34: e626–e628. DOI: 10.1111/jdv.16502.

14. Zubair A.S., Rethana M., Keung B. Brentuximab-Induced Sensorimotor Polyneuropathy with Acquired Demyelinating Features Resembling Chronic Inflammatory Demyelinating Polyneuropathy. Journal of Clinical Neuromuscular Disease. 2022; 23:166–168. DOI: 10.1097/CND.0000000000000352.

15. Fargeot G., Dupel-Pottier C., Stephant M. et al. Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies. Journal of Neurology, Neurosurgery and Psychiatry. 2020; 91: 786–788. DOI: 10.1136/jnnp2020-323124.

16. Seror R., Richez C., Sordet C. et al. Pattern of demyelination occurring during anti-TNF-α therapy: A french national survey. Rheumatol (United Kingdom). 2013; 52 (5):868–874. DOI: 10.1093/rheumatology/kes375.

17. Mariotto S., Ferrari S., Sorio M. et al. Brentuximab vedotin: axonal microtubule’s Apollyon. Blood Cancer J. 2015; 5 (8):e343. DOI: 10.1038/bcj.2015.72.

18. Van Doorn P.A., Van den Bergh P.Y.K, Hadden R.D.M. et al. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome. Eur J Neurol. 2023; 30 (12):3646–3674. DOI: 10.1111/ene.16073.

19. Grimm A., Décard B.F., Axer H., Fuhr P. The Ultrasound pattern sum score — UPSS. A new method to differentiate acute and subacute neuropathies using ultrasound of the peripheral nerves. Clin Neurophysiol. 2015; 126 (11):2216–2225. DOI: 10.1016/j.clinph.2015.01.011.

20. Freites-Martinez A., Santana N., Arias-Santiago S., Viera A. CTCAE versión 5.0. Evaluación de la gravedad de los eventos adversos dermatológicos de las terapias antineoplásicas. Actas Dermosifiliogr. 2021; 112 (1):90–92. DOI: 10.1016/j.ad.2019.05.009.

21. N.А. Suponevа, E.S. Naumovа, E.V. Gnedovskaya. Chronic inflammatory demyelinating polyneuropathy in adults: diagnostic approaches and first line therapy. Neuromuscular Diseases. 2016; 6 (1): 44-53. [In Russian]. DOI: 10.17 650 / 2222-8721-2016-6-1-44-53.